Can a Two-Pronged antibody boost Chemo's power against a tough breast cancer?

This phase 2 trial is testing whether adding an investigational drug called ivonescimab to standard chemotherapy before surgery can improve outcomes for people with triple-negative breast cancer. Ivonescimab is a bispecific antibody that works in two ways: it helps the immune system attack cancer cells and also blocks the tumor's blood supply. The study will compare two different chemo regimens combined with ivonescimab, measuring how often the cancer completely disappears by the time of surgery, and will also track side effects and long-term survival.